How does a risk-benefit analysis factor into regulatory submissions for rehabilitation devices?

• A. It has no role in regulatory submissions.
• B. It solely determines product pricing.
• C. It solely supports labeling decisions.
• D. It supports decisions about acceptable residual risk, informs labeling, and demonstrates safety and effectiveness to regulators.

Answer: (D)

Regulatory submissions require showing that the device’s benefits to patients outweigh the remaining risks after applying risk controls. For rehabilitation devices, this means evaluating what residual risk remains, confirming that its level is acceptable given the expected benefits such as improved function, independence, or safety, and then presenting evidence that the device is safe and effective. This risk-benefit stance also guides labeling—warnings, contraindications, and instructions—so users and clinicians know how to use the device safely and when not to use it. Together, the risk-benefit assessment, labeling decisions, and demonstrated safety and effectiveness form the regulator-facing package.

Pricing is not the focus of regulatory risk-benefit submissions, and labeling considerations are broader than any single aspect, so the other options don’t capture the full regulatory role.